Shensong Yangxin (SSYX) Ameliorates Disordered Excitation Transmission by Suppressing Cardiac Collagen Hyperplasia in Rabbits with Chronic Myocardial Infarction

The traditional Chinese medicine Shensong Yangxin（SSYX） can improve the clinical symptoms of arrhythmia in an integrated manner. This study aimed to investigate the electrophysiological effect of SSYX on the hearts of myocardial-infarcted rabbits and further explore the mechanism by which SSYX alleviates myocardial fibrosis. Myocardial infarction（MI） was established in rabbits by ligation of the left circumflex coronary. The rabbits were treated with SSYX（0.5 g/kg/d） or saline for 8 weeks by oral administration. Microelectrode array（MEA） technology was used in vivo for extracellular electrophysiological recordings of the infarct border zone. Masson＇s trichrome staining was used to observe myocardial fibrosis. Western blotting was performed to evaluate the protein expression levels of collagen Ⅰ（COL Ⅰ） and collagen Ⅲ（COL Ⅲ）. Quantitative real-time polymerase chain reaction（real-time PCR） was performed to evaluate the TGF-β1 and MMP-2 m RNA expression levels. The results showed that the total activation time（TAT） and the dispersion of TAT were significantly increased and the excitation propagation markedly disordered after MI. SSYX could significantly decrease TAT and the dispersion of TAT, and significantly ameliorate the chaotic spread pattern of excitation. Furthermore, SSYX treatment could significantly decrease COL Ⅰ and COL Ⅲ protein levels and down-regulate TGF-β1 and MMP-2 m RNA expression levels in MI rabbits. It was concluded that SSYX may ameliorate cardiac electrophysiological abnormalities in infarcted hearts by decreasing the protein levels of COL Ⅰ and COL Ⅲ, down-regulating the m RNA expression levels of TGF-β1 and MMP2, and thereby reducing adverse cardiac remodeling.

Yangxin Dawayimixike honey paste inhibits atherosclerosis in ApoE^(-/-)mice by attenuating blood lipids and exerting anti-inflammatory activity

Background:Yangxin Dawayimixike honey paste(YDHP)is a representative traditional Chinese medicine,and its main function is curing angina pectoris,palpitation and neurasthenia.However,it is unclear whether YDHP can suppress the development of atherosclerosis.The aim of this study was to validate the potential application of YDHP in atherosclerosis therapy and search for its potential mechanisms.Methods:Seven-week-old ApoE^(-/-)mice were randomly divided into a normal group fed a normal diet,an atherosclerosis model group fed a high-fat diet,YDHP groups fed a high-fat diet mixed with different doses of YDHP and positive control groups fed a high-fat diet mixed with atorvastatin or rosuvastatin.After feeding for 10 weeks,body weight,blood lipids,liver and kidney function indexes,serum inflammatory cytokines and atherosclerotic plaque areas were measured.Serum metabolic profiles were detected by an automatic biochemical analyser.Serum inflammatory cytokines were quantified by enzyme-linked immunosorbent assay kits.Atherosclerotic plaque areas were analysed using Oil Red O staining.Results:The YDHP(200,400 and 800 mg/kg/d)treated groups showed reduced serum levels of low density lipoprotein-cholesterol(P<0.05,when 200 or 400 mg/kg/d of YDHP group compared with the atherosclerosis model group;P<0.01,when 800 mg/kg/d of YDHP group compared with the atherosclerosis model group),total cholesterol(P<0.05,when 200 mg/kg/d of YDHP group compared with the atherosclerosis model group;P<0.01,when 400 or 800 mg/kg/d of YDHP group compared with the atherosclerosis model group)and triglyceride(P<0.01),however,elevated serum levels of high-density lipoprotein cholesterol(P<0.01)compared to the atherosclerosis model group.YDHP inhibited the area of atherosclerotic lesions.In addition,YDHP suppressed the levels of serum inflammatory cytokines such as interleukin 6(P<0.05,when 200 mg/kg/d of YDHP group compared with the atherosclerosis model group;P<0.01,when 400 or 800 mg/kg/d of YDHP group compared with the atherosclerosis model group)and tumor necrosis factorα(P<0.05,when 200 mg/kg/d of YDHP group compared with the atherosclerosis model group;P<0.01,when 400 or 800 mg/kg/d of YDHP group compared with the atherosclerosis model group).Conclusion:Our study demonstrated that YDHP showed considerable activity in alleviating the formation of atherosclerotic plaques in ApoE^(-/-)mice by reducing blood lipids and exerting anti-inflammatory activity.

Discussion on moment tensor solution and seismogenic structure of Ruichang-Yangxin earthquake on 10 September 2011

Ruichang-Yangxin earthquake is another moderate earthquake in Yangxin-Jiujiang area since 2005 Jiujiang-Ruichang M5.7 earthquake. In order to more understand the seismic activities in this area, we study the moment tensor solution and the seismogenic structure of the Ruichang-Yangxin earthquake. Precise earthquake relocation shows that the mainshock occurred on the southwestern part of the NE-trending fault and aftershocks are distributed not only along the NE-trending fault but also along its conjugated NW-trending fault. By comprehensive analysis on the earthquake distribution, characteristics of isoseismal curve, focal mechanism, and regional structure characteristics, it is inferred that this earthquake is caused by the NE-trending Tanlu fault. In addition, it has close relationship with the conjugated NW-trending fault as well. Many researches have shown that the junction area is the earthquake-prone area, and should be paid more attention to. And our study also proves this viewpoint.

Analysis on the Effects of Shensong Yangxin Capsules and Amiodarone on Heart Rate Variability Indices and Inflammatory Factors in Patients with Arrhythmia

Objective:To study the effects of Shensong Yangxin capsules and amiodarone on heart rate variability indexes and inflammatory factors in the treatment of patients with arrhythmia.Methods:The research subjects were selected patients with arrhythmia admitted in our hospitaFs department from October 2018 to October 2019,and a total of 70 patients were divided into two groups.35 subjects in the control group were treated with amiodarone alone,and 35 subjects in the observation group were treated with Shensongyangxin capsule in combination with amiodarone for comparisons in treatment effects,heart rate variability indices,inflammatory factors,and adverse reactions.Results:After observation,the treatment efficiency in the observation group was higher than that in the control group(P<0.05).Before treatment,there was no difference in heart rate variability indices between the two groups(P>0.05),after treatment,the improvement in patients of the observation group was better than that of the control group(P<0.05).After treatment,the inflammatory factors of the two groups of patients decreased,and the indicators of the observation group were comparably lower than those of the control group(P<0.05).In the comparison of adverse reactions,the observation group showed a lower incidence of adverse reactions after treatment than the control group(P<0.05).Conclusion:In the treatment of patients with arrhythmia,the combined use of Shensong Yangxin capsules and amiodarone has more significant therapeutic effects,which can effectively improve the patient's heart rate variability indices,reduce the inflammatory factors,and relieve the symptoms in patients.The incidence of adverse reactions is low and the safety is quite high,therefore it has great value in clinical applications.

Meta Analysis and Cost-effectiveness of Yangxin Dingji Capsule in the Treatment of Tachyarrhythmia

[Objectives] To compare the clinical efficacy and cost-effectiveness of Yangxin Dingji capsule in conjunction with conventional Western medicine therapy against the use of conventional Western medicine therapy alone in the treatment of tachyarrhythmia.[Methods] A meta-analysis was conducted to evaluate the efficacy of Yangxin Dingji capsule in conjunction with conventional Western medicine therapy for the treatment of tachyarrhythmia, compared to conventional Western medicine therapy alone. A decision tree model was developed to conduct a cost-effectiveness analysis from the perspective of the healthcare system. The effect parameter was the clinical effectiveness rate obtained from a meta-analysis of clinical literature. The cost parameter was represented by the drug treatment cost. The incremental cost-effectiveness ratio (ICER) was subsequently calculated, and the robustness of the primary analysis results was assessed through one-way sensitivity analysis.[Results] The results of the meta-analysis indicated that, over an 8-week treatment period, the clinical efficacy of Yangxin Dingji capsule in conjunction with conventional Western medicine for the treatment of tachyarrhythmia was superior to that of conventional Western medicine therapy alone, and the difference was found to be statistically significant [ OR =3.32, 95% CI (2.22-4.96), P <0.000 01]. The clinical efficacy of Yangxin Dingji capsule in conjunction with conventional Western medicine for the treatment of tachyarrhythmia was found to be superior when the treatment duration was 4 weeks, and the difference was found to be statistically significant [ OR =2.39, 95% CI (1.45-3.96), P =0.000 7]. The cost-effectiveness analysis indicated that with an 8-week treatment regimen, each 1% increase in the clinical effectiveness rate of Yangxin Dingji capsule in conjunction with conventional Western medical therapy for the treatment of arrhythmia, as compared to conventional Western medical therapy alone, resulted in an increase in cost of 91.78 yuan. Conversely, when the treatment duration was 4 weeks, each 1% increase in the clinical effectiveness rate of the Yangxin Dingji capsule combined with conventional Western medical therapy led to a cost increase of 70.84 yuan.[Conclusions] In the management of tachyarrhythmia, the clinical efficacy of Yangxin Dingji capsule in conjunction with conventional Western medicine therapy is superior to that of conventional Western medicine therapy alone. When the willingness-to-pay value exceeds the corresponding ICER, the combination of Yangxin Dingji capsule with conventional Western medicine therapy is deemed more cost-effective than the use of conventional Western medicine therapy alone.

Effects of Traditional Chinese Medicine Shensong Yangxin Capsules on Heart Rhythm and Function in Congestive Heart Failure Patients with Frequent Ventricular Premature Complexes：A Randomized, Double-blind, Multicenter Clinical Trial

Background：Pharmacological therapy for congestive heart failure （CHF） with ventricular arrhythmia is limited.In the study,our aim was to evaluate the effects of Chinese traditional medicine Shensong Yangxin capsules （SSYX） on heart rhythm and function in CHF patients with frequent ventricular premature complexes （VPCs）.Methods：This double-blind,placebo-controlled,multicenter study randomized 465 CHF patients with frequent VPCs to the SSYX （n =232） and placebo groups （n =233） for 12 weeks of treatment.The primary endpoint was the VPCs monitored by a 24-h ambulatory electrocardiogram.The secondary endpoints included the left ventricular ejection fraction （LVEF）,left ventricular end-diastolic diameter,N-terminal pro-brain natriuretic peptide （NT-proBNP）,New York Heart Association （NYHA） classification,6-min walking distance （6MWD）,Minnesota Living with Heart Failure Questionnaire （MLHFQ） scores,and composite cardiac events （CCEs）.Results：The clinical characteristics were similar at baseline.SSYX caused a significantly greater decline in the total number of VPCs than the placebo did （-2145 ± 2848 vs.-841 ± 3411,P 〈 0.05）.The secondary endpoints of the LVEE NYHA classification,NT-proBNP,6MWD,and MLHFQ scores showed a greater improvements in the SSYX group than in the placebo group （ALVEF at 12th week：4.75 ± 7.13 vs.3.30 ± 6.53;NYHA improvement rate at the 8th and 12th week：32.6% vs.21.8%,40.5% vs.25.7%;mean level of NT-proBNP in patients with NT-proBNP 〉125 pg/ml at 12th week：-122 [Q1,Q3：-524,0] vs.-75 [Q1,Q3：-245,0];A6MWD at 12th week：35.1 ± 38.6 vs.17.2 ± 45.6;AMLHFQ at the 4th,8th,and 12th week：-4.24 ± 6.15 vs.-2.31 ± 6.96,-8.l 9 ± 8.41 vs.-3.25 ± 9.40,10.60 ± 9.41 vs.-4.83 ± 11.23,all P 〈 0.05）.CCEs were not different between the groups during the study period.Conclusions：In this 12-week pilot study,SSYX was demonstrated to have the benefits of VPCs suppression and cardiac function improvement with good compliance on a background of standard treatment for CHF.

Mineral chemistry, geochemistry and U-Pb SHRIMP zircon data of the Yangxin monzonitic intrusive in the foreland of the Dabie orogen

The Yangxin composite intrusive consists of three generations of plutons, among which 90% are the second generation intrusions. The second generation intrusion has U-Pb SHRIMP zircon age of 134±2 Ma, substantially younger than the early stage of the Yanshanian. Amphibole and biotite, major mafic minerals in the Yangxin plutons, are rich in magnesium, suggesting a deep source of their parental magma, possibly derived from the upper mantle. Whole rock geochemical data on these rocks show that they have high Al2O3 (15.92%―16.38%), relatively high alkali (Na2O+K2O = 6.95%―7.37%) and higher Na2O contents than K2O (Na2O/K2O = 1.47―1.94). They also have high Sr con-tents (816―897 μg/g) are enriched in strong incompatible elements such as Rb, U, Th, K and LREE, but depleted in HREE and Y. Strong fractionation of LREE from HREE as indicated by high (La/Yb)N ratios ranging from 17.83 to 20.86. Although with little difference, the whole characteristics of the Yangxin intrusive body are greatly similar to the adakite, referring that the formation of the parental magma may relate with the partial melting of the basalt underplating from the mantle after delamina-tion of the mountain root of the Dabie orogen. The body has been uplifted about 5 km since cooling concretion, the average rate was only about 0.04 mm/a,much slower than that of the Dabie orogen in late Mesozoic, but the rates of denudation in two area are similar in Cenozoic.

Effect of the Shensong Yangxin Capsule on Energy Metabolism in Angiotensin II-lnduced Cardiac Hypertrophy

Background：Shensong Yangxin Capsule （SSYX）,traditional Chinese medicine,has been used to treat arrhythmias,angina,cardiac remodeling,cardiac fibrosis,and so on,but its effect on cardiac energy metabolism is still not clear.The objective of this study was to investigate the effects of SSYX on myocardium energy metabolism in angiotensin （Ang） Ⅱ-induced cardiac hypertrophy.Methods：We used 2 μl （10-6 mol/L） AngⅡ to treat neonatal rat cardiomyocytes （NRCMs） for 48 h.Myocardial α-ac tinin staining showed that the myocardial cell volume increased.Expression of the cardiac hypertrophic marker-brain natriuretic peptide （BNP） messenger RNA （mRNA） also increased by real-time polymerase chain reaction （PCR）.Therefore,it can be assumed that the model of hypertrophic cardiomyocytes was successfully constructed.Then,NRCMs were treated with 1 μl of different concentrations of SSYX （0.25,0.5,and 1.0 μg/ml） for another 24 h.To explore the time-depend effect of SSYX on energy metabolism,0.5 μg/ml SSYX was added into cells for 0,6,12,24,and 48 h.Mitochondria was assessed by MitoTracker staining and confocal microscopy.mRNA and protein expression of mitochondrial biogenesis-related genes-Peroxisome proliferator-activated receptor-γ coactivator-1 α （PGC-1 α）,energy balance key factor -adenosine monophosphate-activated protein kinase （AMPK）,fatty acids oxidation factor-camitine palmitoyltransferase-1 （CPT-1）,and glucose oxidation factor-glucose transporter-4 （GLUT-4） were measured by PCR and Western blotting analysis.Results：With the increase in the concentration of SSYX （from 0.25 to 1.0 μg/ml）,an increased mitochondrial density in Angll-induced cardiomyocytes was found compared to that of those treated with Angll only （0.25 μg/ml,18.3300 ± 0.8895 vs.24.4900 ± 0.9041,t =10.240,P 〈 0.0001;0.5 μg/ml,18.3300 ± 0.8895 vs.25.9800 ± 0.8187,t =12.710,P 〈 0.0001;and 1.0 μg/ml,18.3300 ± 0.8895 vs.24.2900 ± 1.3120,t =9.902,P 〈 0.0001;n =5 per dosage group）.SSYX also increased the mRNA and protein expression ofPGC-1α （0.25 μg/ml,0.8892 ± 0.0848 vs.1.0970 ± 0.0994,t =4.319,P =0.0013;0.5 μg/ml,0.8892 ± 0.0848 vs.1.2330 ± 0.0564,t =7.150,P 〈 0.0001;and 1.0 μg/ml,0.8892 ± 0.0848 vs.1.1640 ± 0.0755,t =5.720,P 〈 0.0001;n =5 per dosage group）,AMPK （0.25 μg/ml,0.8872 ± 0.0779 vs.1.1500 ± 0.0507,t =7.239,P 〈 0.0001;0.5 μg/ml,0.8872 ± 0.0779 vs.1.2280 ± 0.0623,t =9.379,P 〈 0.0001;and 1.0 μg/ml,0.8872 ± 0.0779 vs.1.3020 ± 0.0450,t =11.400,P 〈 0.0001;n =5 per dosage group）,CPT-1 （1.0 μg/ml,0.7348 ± 0.0594 vs.0.9880 ± 0.0851,t =4.994,P =0.0007,n =5）,and GLUT-4 （0.5 μg/ml,1.5640 ± 0.0599 vs.1.7720 ± 0.0660,t =3.783,P =0.0117;1.0 μg/ml,1.5640 ± 0.0599 vs.2.0490 ± 0.1280,t =8.808,P 〈 0.0001;n =5 per dosage group）.The effect became more obvious with the increasing concentration of SSYX.When 0.5 μg/ml SSYX was added into cells for 0,6,12,24,and 48 h,the expression of AMPK （6 h,14.6100 ± 0.6205 vs.16.5200 ± 0.7450,t =3.456,P =0.0250;12 h,14.6100 ± 0.6205 vs.18.3200 ± 0.9965,t =6.720,P 〈 0.0001;24 h,14.6100 ± 0.6205 vs.21.8800 ± 0.8208,t =13.160,P 〈 0.0001;and 48 h,14.6100 ± 0.6205 vs.23.7400 ± 1.0970,t =16.530,P 〈 0.0001;n =5 per dosage group）,PGC-1α （12 h,11.4700 ± 0.7252 vs.16.9000 ± 1.0150,t =7.910,P 〈 0.0001;24 h,11.4700 ± 0.7252 vs.20.8800 ± 1.2340,t =13.710,P 〈 0.0001;and 48 h,11.4700 ± 0.7252 vs.22.0300 ± 1.4180,t =15.390;n =5 per dosage group）,CPT-1 （24 h,15.1600 ± 1.0960 vs.18.5800 ± 0.9049,t =6.048,P 〈 0.0001,n =5）,and GL UT-4 （6 h,10.2100 ± 0.9485 vs.12.9700 ± 0.8221,t =4.763,P =0.0012;12 h,10.2100± 0.9485 vs.16.9100± 0.8481,t=1 1.590,P〈 0.0001;24 h,10.2100±0.9485 vs.19.0900± 0.9797,t=15.360,P〈 0.0001;and 48 h,10.2100 ± 0.9485 vs.14.1900 ± 0.9611,t =6.877,P 〈 0.0001;n =5 per dosage group） mRNA and protein increased gradually with the prolongation of drug action time.Conclusions：SSYX could increase myocardial energy metabolism in AngⅡ-induced cardiac hypertrophy.Therefore,SSYX might be considered to be an alternative therapeutic remedy for myocardial hypertrophy.

Impact of 60 Days of 6° Head Down Bed Rest on Cardiopulmonary Function,and the Effects of Taikong Yangxin Prescription(太空养心方) as A Countermeasure

Objective： To study the changes in cardiopulmonary function induced by mid/long-term simulated microgravity with 6^° head down bed rest （HDBR）, and the effects of Taikong Yangxin Prescription （太空养心方, TYP） as a countermeasure. Methods： Fourteen healthy male volunteers were randomly divided into a control group and a Chinese medicine （CM） group （7 in each group） by a random digital table based on their body weight. Both groups underwent6^° HDBR for 60 days. Subjects in the CM group received daily TYP pills and subjects in the control group received daily placebo pills. Cardiac systolic and pumping functions were measured by echocardiography before HDBR; on days 20, 42, and 57 of HDBR; and on day 3 of recovery after HDBR （R＋3）. Cardiopulmonary functional reserve and exercise capacity were evaluated before HDBR, on day 29, and on day R＋3 by exercise testing. Results： The heart rate （HR） increased gradually during HDBR. The HR was significantly higher on day 57 than before HDBR in the control group （P〈0.05）, but did not increase significantly in the CM group. The stroke volume/stroke volume index, ejection fraction, and left ventricular fractional shortening tended to decrease over time in the control group, but not in the CM group. These parameters were significantly higher in the CM group than in the control group on day 42 （P〈0.05 or P〈0.01）. Exercise testing showed that maximum 02 consumption （VO2max）, metabolic equivalents, relative 02 consumption （VO2）, 02 pulse, and exercise duration were significantly lower on day 29 than before HDBR in the control group, but not in the CM group. Conclusions： Sixty days of 6^° HDBR induced a reduction in cardiac systolic and pumping functions, and reduced cardiopulmonary functional reserve and exercise capacity. Administration of TYP significantly improved cardiac systolic and pumping functions, and maintained cardiopulmonary functional reserve and exercise capacity.

Effects of Shensong Yangxin capsule on pacemaker channels encoded by human HCN4 gene

Shensong Yangxin （SSYX） is one of the compound recipes of Chinese materia medica including 12ingredients such as Panax ginseng, dwarf lilyturf tuber,nardostachys root, etc. Small-scale randomized multi-centre clinical trials suggested that SSYX reduced the number of ventricular extrasystoles in patients with or without structural heart disease.1 Besides excellent antiarrhythmic efficacy,2 SSYX also improved bradycardia in some patients, which was evidenced by animal studies3 as well.

Effect of Shenqi Yangxin decoction on high mobility group box 1and inflammatory signal pathway in a rat model of dilated cardiomyopathy

OBJECTIVE: To investigate the effects of Shenqi Yangxin decoction(SQYXD) on heart function in a rat model of dilated cardiomyopathy(DCM) and its potential mechanisms.METHODS: Sprague-Dawley rats were randomly divided into normal(10 rats) and DCM(150 rats)groups. DCM was induced by an intraperitoneal injection of adriamycin. Then, DCM baseline group was randomly selected sixteen DCM rats. The remaining DCM rats were randomly divided into DCM control, perindopril, metoprolol, and SQYXD groups. Cardiac function and histological analysis plus biochemical measurement of serum levels of brain natriuretic peptide(BNP), and inflammatory factors were measured. The mRNA and protein expression levels of high-mobility group box 1(HMGB1), Toll-like receptor 4(TLR-4), receptor for advanced glycation end products(RAGE), and nuclear factor-κB(NF-κB) were determined. Myocardial metabolism imaging was performed on the normal, SQYXD and DCM control groups to evaluate the effectiveness of treatments.RESULTS: Rats in the DCM control group exhibited dilated left ventricular diameter, impaired cardiac function, disorganized sarcomere, impaired glucose metabolism, increased heart weight index,and increased levels of BNP, which were improved by treatment with SQYXD. In addition, hearts from rats in the DCM baseline group exhibited significantly higher levels of HMGB1, TLR-4, RAGE, NF-κB,tumor necrosis factor-α, interleukin-1, interleukin-6, interleukin-10, compared with the normal group. Interestingly, the mRNA level of HMGB1 in the DCM baseline group was positively correlated with that of TLR-4, RAGE, NF-κB, BNP, and LVEDD,but negatively correlated with LVEF. SQYXD inhibited the upregulation of HMGB1 expression and its downstream inflammatory factors.CONCLUSION: Shenqi Yangxin decoction effectively reduced the dilated left ventricular diameter and improved heart function in dilated cardiomyopathy. The mechanisms underlying the action on DCM involve regulating the gene and protein expression of HMGB1 and its inflammatory signal pathways in the DCM rat model.

Chinese Medicine Shensong Yangxin Capsule(参松养心胶囊)Ameliorates Myocardial Microcirculation Dysfunction in Rabbits with Chronic Myocardial Infarction

Objective:To investigate the effect of Chinese compound Shensong Yangxin Capsule(参松养心胶囊,SSYX)on myocardial microcirculation in myocardial-infarcted rabbits.Methods:Myocardial infarction(MI)was established in rabbits by ligation of the left circumflex coronary.Thirty rabbits were randomly divided into the control group,the MI group(model),and the MI treated with SSYX group(MI+SSYX)by a random number table method.After 4 weeks of administration,low-energy real-time myocardial contrast echocardiography(RT-MCE)was conducted to assess the microcirculatory perfusion.Immunofluorescence double staining was used to detect the capillary density.The endothelial ultrastructure was observed with a transmission electron microscope.The m RNA expression levels of vascular endothelial growth factor(VEGF),endothelin 1(ET-1),prostaglandin I2(PGI2)and endothelial nitric oxide synthase(e NOS)were measured by real-time quantitative polymerase chain reaction(Real-time PCR).The plasmic levels of ET-1,thromboxane A2(TXA2),nitric oxide(NO)and von willebrand factor(v WF)were examined with enzyme-linked immunosorbent assays(ELISA).Results:SSYX significantly improved the myocardial blood volume,myocardial micro bubble velocity,and myocardial inflow according to the examination of RT-MCE,and it visibly ameliorated the capillary endothelial structure.Furthermore,compared with the MI group,the plasma levels of TXA2,ET-1 and v WF contents significantly decreased in the MI+SSYX group,and the ET-1 mRNA expression levels of myocardium in the border zone significantly decreased,and the VEGF,PGI2 and e NOS m RNA expression levels significantly increased(all P<0.05).Conclusions:SSYX has favorable advantages in ameliorating the impaired myocardial microcirculation following MI.The mechanisms of the effect are related to the ability of SSYX in balancing the endothelial-derived vasodilators and vasoconstrictors,and up-regulating the expression of VEGF and e NOS.

Simultaneous Determination of Eight Bioactive Constituents in Shensong Yangxin Capsule by UPLC

Objective To develop a ultra performance liquid chromatography(UPLC) method for the quality evaluation of Shensong Yangxin Capsule(SYC).Methods The Waters Acquity UPLC HSS T3 column(100 mm × 2.1 mm,1.8μm) was used.Acetonitrile and water containing 0.1% phosphoric acid were used as mobile phases of UPLC with gradient elution.The detection wavelengths were set at 203(ginsenoside Rb1),286(salvianolic acid B),230(paeoniflorin),221(schisantherin A),280(sodium danshensu),327(chlorognenic acid),335(spinosin),and 345nm(berberine hydrochloride),respectively.The flow rate was set at 0.4 mL/min and column temperature was 35 ℃.Results The contents of paeoniflorin,salvianolic acid B,schisantherin A,sodium danshensu,chlorognenic acid,spinosin,berberine hydrochloride,and ginsenoside Rb1were determined from 10 batches of SYC.Conclusion The method of the quality evaluation of SYC has acceptable precision,reproducibility,and stability,which could be used as a new method for the quality control of SYC.

A pilot study of traditional Chinese medicine Shensong Yangxin capsule in patients with premature ventricular contractions and bradycardia

Background Management of premature ventricular contractions （PVCs） and bradycardia is difficult, because most antiarrhythmic drugs may lead to more severe bradycardia, so other effective drugs with less side effects are alternatives for treating those patients. To evaluate the efficacy and safety of the traditional Chinese medicine Shensong Yangxin capsule （SYC） in patients with bradycardia and PVCs, a pilot study was conducted. Methods One hundred and sixty-eight patients with bradycardia and PVCs were randomly assigned to receive either SYC （trial group, = 86） or placebo （control group, = 82） for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, quality of life, hepatic function and renal were evaluated at baseline and after 4-week treatment. Results The average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the baseline and the control group after 4-week follow-up （ 〈 0.01, 0.05, 0.05, respectively.）. Compared with pretreatment, the PVCs in the trial group decreased significantly after treatment （1911.7 ±402.6 vs. 5550.1 ± 973.7, 〈 0.01）. Both the quality of life and the symptom scores in the trial group were significantly better than those in the control group. No severe adverse effects were reported. Conclusion SYC is effective and safe for the treatment of PVCs and bradycardia and improves the symptoms and quality of life.

参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭对hs-CRP、BNP、AngⅡ及心功能的影响

目的 探讨参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭对高敏C反应蛋白(High sensitivity C-reactive protein, hs-CRP)、脑钠肽(Brain natriuretic peptide, BNP)、血管紧张素Ⅱ(AngiotensinⅡ,AngⅡ)及心功能的影响。方法 选取100例阵发性心房颤动合并慢性心力衰竭患者,随机分为对照组与观察组,每组50例,对照组在常规治疗基础上给予沙库巴曲缬沙坦口服,观察组在常规治疗基础上给予参松养心胶囊联合沙库巴曲缬沙坦口服治疗,疗程6个月。观察血清hs-CRP、BNP、AngⅡ、左心室射血分数(Left ventricular ejection fraction, LVEF)、左室收缩末期内径(Left ventricular end systolic diameter, LVESD)、左室舒张末期内径(Left ventricular end diastolic diameter, LVEDD)变化。结果 两组治疗前血清hs-CRP、BNP、AngⅡ比较差异无统计学意义(P>0.05),治疗后下降(P<0.05),且观察组低于对照组(P<0.05);两组治疗前LVEF、LVESD、LVEDD比较差异无统计学意义(P>0.05),治疗后LVEF升高(P<0.05),且观察组高于对照组(P<0.05),治疗后LVESD、LVEDD下降(P<0.05),且观察组低于对照组(P<0.05);两组治疗前阵发性心房颤动发作次数、阵发性心房颤动持续时间、心室率比较差异无统计学意义(P>0.05),治疗后下降(P<0.05),且观察组低于对照组(P<0.05);对照组转为持续性心房颤动、心力衰竭恶化、缺血心源性死亡率分别为20.00%、22.00%、4.00%,观察组分别为4.00%、6.00%、0.00%,转为持续性心房颤动、心力衰竭恶化发生率对照组高于观察组(P<0.05);观察组治疗疗效优于对照组(P<0.05)。结论 参松养心胶囊联合沙库巴曲缬沙坦治疗阵发性心房颤动合并慢性心力衰竭有助于促进hs-CRP、BNP、AngⅡ下降,改善患者心功能,改善预后。

参松养心胶囊治疗老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床观察

目的:观察参松养心胶囊对老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床疗效、动态心电图室性早搏次数及中医证候积分的影响。方法:选择老年冠心病室性早搏气阴两虚、心络瘀阻型患者60例,按照随机数字表法分为对照组和观察组,每组30例。对照组给予口服酒石酸美托洛尔,观察组在对照组基础上口服参松养心胶囊。两组均连续治疗4周。观察两组治疗前后临床疗效,24 h动态心电图室性早搏次数及中医证候积分。结果:对照组有效率[73.33%(22/30)]高于观察组[96.67%(29/30)](P<0.05)。两组治疗后室性早搏次数均减少,观察组减少较对照组更明显(P<0.05)。与治疗前比较,两组心悸、悸动不安、神疲乏力、气短、五心烦热等中医证候积分均下降(P<0.05),且治疗后观察组上述指标改善优于对照组(P<0.05)。结论:参松养心胶囊能有效减少老年冠心病室性早搏患者的室性早搏次数,改善患者临床症状。

益气养心方治疗冠心病室性心律失常的疗效及其对心肌缺血的血液流变学指标、CXCL9水平的影响

目的观察益气养心方治疗冠心病室性心律失常的临床疗效及其对心肌缺血的血液流变学指标、CXC趋化因子配体9(CXCL9)水平的影响。方法选取2021年6月至2022年12月在该院治疗的70例冠心病室性心律失常患者作为研究对象,采用随机数字表法分为对照组和观察组,每组35例。两组患者均实施常规对症治疗,对照组在常规对症治疗的基础上给予酒石酸美托洛尔片治疗,观察组在对照组的基础上给予益气养心方治疗,两组患者均连续治疗4个月。观察两组临床疗效、血液流变学指标水平、血清CXCL9水平及不良反应情况。结果观察组治疗后总有效率高于对照组(P<0.05);两组治疗后全血低切黏度、全血高切黏度、血浆比黏度、纤维蛋白水平均低于治疗前,且观察组均低于对照组(P<0.05);两组治疗后血清CXCL9水平均低于治疗前,且观察组低于对照组(P<0.05);两组治疗过程中均未见严重不良反应,仅有极少数患者出现轻微恶心、呕吐症状。结论益气养心方治疗冠心病室性心律失常临床疗效较佳,可调低血清CXCL9水平,减轻心肌损伤,改善心肌的血液流变学指标,促进心律失常改善,且治疗安全性较高。

参松养心胶囊联合阿托伐他汀治疗对冠心病患者血脂、动脉粥样硬化的效果

目的 探讨参松养心胶囊联合阿托伐他汀治疗对冠心病患者血脂、动脉粥样硬化的效果。方法 选取72例冠心病患者作为研究对象,将其随机分为对照组和研究组,每组36例。对照组行口服阿托伐他汀钙片治疗,研究组在对照组的基础上加用参松养心胶囊治疗,两组均治疗6个月。比较两组治疗前、治疗6个月后的血脂水平、颈动脉内-中膜厚度(IMT)、脉搏波传导速率(PWV),以及治疗期间不良心血管事件的发生情况。结果 治疗6个月后,对照组低密度脂蛋白胆固醇(LDL-C)水平低于治疗前;研究组总胆固醇、甘油三酯、LDL-C水平均低于治疗前,且均低于对照组;研究组颈动脉IMT、PWV均低于对照组(均P<0.05)。治疗期间,两组均无不良心血管事件的发生。结论 参松养心胶囊可以改善冠心病患者的血脂代谢,有效调理血脂,并改善患者的动脉粥样硬化,降低急性心血管事件的发生风险。

养心定悸胶囊对心肌缺血再灌注损伤大鼠心肌细胞自噬和凋亡的影响

目的:探讨养心定悸胶囊对心肌缺血再灌注损伤(MIRI)大鼠心肌细胞自噬和凋亡的影响。方法:将30只成年雄性SD大鼠随机分为5组(假手术组、模型组与低、中、高剂量养心定悸组),每组6只。使用ELISA试剂盒检测各组大鼠血清中心肌损伤标志物含量,Tunel法检测各组大鼠心肌组织细胞凋亡情况,Western blot法检测各组大鼠心肌组织凋亡和自噬相关蛋白表达情况。结果:与模型组比较,养心定悸胶囊低、中、高剂量组大鼠血清肌钙蛋白I(cTnI)、肌酸激酶(CK)和乳酸脱氢酶(LDH)水平下降,差异均有统计学意义(P<0.05),高剂量组降低最明显;养心定悸胶囊各剂量组大鼠心肌细胞凋亡数量减少,心肌细胞B淋巴细胞瘤-2基因(Bcl-2)、磷酸化磷脂酰肌醇3激酶(p-PI3K)和磷酸化丝氨酸/苏氨酸激酶(p-Akt)、磷酸化哺乳动物雷帕霉素靶蛋白(p-mTOR)表达水平明显升高,差异均有统计学意义(P<0.05),激活型半胱氨酸蛋白酶-3(cleaved Caspase-3)、激活型半胱氨酸蛋白酶-9(cleaved Caspase-9)和Bcl-2基因关联X(Bax)蛋白、微管相关蛋白轻链(LC3II/I)和自噬效应蛋白(Beclin1)表达水平降低,差异均有统计学意义(P<0.05),并呈剂量依赖性。结论:养心定悸胶囊通过抑制心肌细胞凋亡和自噬对MIRI大鼠的心肌发挥保护作用,这一作用可能与PI3K/Akt/mTOR通路相关。

古建筑落叶松木构件自然老化材性变化

为探究古建筑木构件自然老化材性变化,以距今约350 a的一段古建筑华北落叶松木构件及与其具有相似年轮宽度的落叶松新材为研究对象,加工标准力学试件,测定试件的材性参数(颜色、全干密度、力学性能参数)及无损检测参数(微钻阻力值、超声波波速),对比分析自然老化木材试件的无损检测参数与材性参数的变化及分布规律,并基于所测得的新旧材两类试件的材性及无损检测参数建立落叶松木材物理力学性能参数的多元回归模型;研究结果表明:所测老化木材试件物理力学参数及无损检测参数均衰减明显,且颜色具有极显著差别;自然老化木材试件各参数变异系数均高于新材试件,但两者均符合正态分布,建立的落叶松木构件物理力学性能参数的评估模型具有较高评估性能。